

# RETURN TO YOU

Keep recurrent  
*C. diff* infection from  
coming back with  
one dose of REBYOTA®



## INDICATION

REBYOTA (fecal microbiota, live - js1m) is indicated for the prevention of recurrence of *Clostridioides difficile* (*C. diff*) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent *C. diff* infection.

## Limitation of Use

REBYOTA is not indicated for the treatment of *C. diff* infection.

## IMPORTANT SAFETY INFORMATION

You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.

**Please see Important Safety Information throughout and on page 11. Click to see full [Prescribing Information](#).**

Scan to visit  
[REBYOTA.com](https://REBYOTA.com)



# ABOUT REBYOTA®

## REBYOTA is...



### A microbiome-based therapy

REBYOTA is a microbiome-based therapy to keep recurrent *C. diff* infection from coming back. It is not an antibiotic.<sup>1</sup>



### A mix of important bacteria

REBYOTA is made up of a consistent mix of important bacteria.<sup>1</sup>



### Delivered where it's needed

In one dose and one visit, REBYOTA is delivered right where it's needed—your gut microbiome.



### Administered within minutes

REBYOTA is administered within minutes. It does not require laxatives/bowel prep, fasting, anesthesia, or colonoscopy.<sup>2</sup>

## IMPORTANT SAFETY INFORMATION (Continued)

You should report to your doctor any infection you think you may have acquired after administration.

**Please see Important Safety Information throughout and on page 11. Click to see full [Prescribing Information](#).**



# REBYOTA® RESULTS

In a major clinical study with REBYOTA<sup>1,a</sup>

REBYOTA After  
Antibiotics

**71%**

success rate<sup>1,b</sup>

Antibiotics  
Alone

**58%**

success rate<sup>1,b</sup>

Of those patients who saw success with REBYOTA<sup>b</sup>...  
**~90% stayed free of *C. diff* at 6 months.<sup>2</sup>**

Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).<sup>3</sup> In clinical studies, there were no serious adverse events related to REBYOTA.<sup>1</sup>

<sup>a</sup>The study was conducted in approximately 300 adult patients with recurrent *C. diff* infection for up to 8 weeks to find out how well REBYOTA prevented recurrent *C. diff* infection. Patients in this study first completed treatment with antibiotics.<sup>1,2</sup>

<sup>b</sup>Success rate indicates no other recurrence of *C. diff* infection at 8 weeks.<sup>2</sup>



## IMPORTANT SAFETY INFORMATION (Continued)

REBYOTA may contain food allergens.

Please see Important Safety Information throughout and on page 11. Click to see full [Prescribing Information](#).

  
**REBYOTA®**  
(fecal microbiota, live-jslm) suspension,  
for rectal use

# GETTING **REBYOTA**®



**When discussing administration, talk to your doctor about your location options.**



## **REBYOTA administration in your doctor's office**

REBYOTA can be administered right in your doctor's office once you've completed your course of antibiotics. After administration, there is a 15-minute wait period, after which you can go home.



## **REBYOTA @ Home**

If you are unable to receive REBYOTA in your doctor's office, you may benefit from the option of administration via home health in the comfort of your home.

## **IMPORTANT SAFETY INFORMATION (Continued)**

REBYOTA has not been studied in patients below 18 years of age.

Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

**Please see Important Safety Information throughout and on page 11. Click to see full [Prescribing Information](#).**





# GETTING READY FOR ADMINISTRATION<sup>1</sup>

Watch as a nurse shows  
you what to expect  
before, during, and after  
administration of REBYOTA.



## Before administration

### No preparation is required

- You should complete your antibiotic prescription 1 to 3 days before your REBYOTA administration appointment
- No laxatives/bowel prep or fasting are required



## During administration

### Takes place within minutes

- Anesthesia or colonoscopy are not necessary
- The doctor or nurse will place you in the preferred position for the administration
- You will be asked to remain in place for about 15 minutes to minimize any cramping that may occur



## After administration

### Follow your doctor's instructions

Talk to your doctor...

- If you experience any side effects
- Before taking antibiotics for any reason for 8 weeks after administration of REBYOTA

**Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.<sup>1</sup>** These side effects could occur during the first 2 weeks after administration.<sup>3</sup> This may not mean your recurrent *C. diff* has come back.

**Please see Important Safety Information throughout and on page 11. Click to see full [Prescribing Information](#).**





## REBYOTA® SUPPORT

### REBYOTA Co-pay Program

**Commercially insured, eligible patients can save on each prescription with the REBYOTA Co-pay Program.**

- For commercially insured individuals whose insurance plans cover REBYOTA
- Must be 18 years of age or older
- Offer valid only in the US
- Must have been administered REBYOTA for an FDA-approved indication

**To enroll in the REBYOTA Co-pay Program, please speak with your doctor. For additional assistance, call 1-877-REBYOTA.**

### REBYOTA Patient Assistance Program<sup>a</sup>

**You may be eligible to receive REBYOTA at no cost if you qualify for the Ferring REBYOTA Patient Assistance Program. Ask your doctor's office to enroll on your behalf through REBYOTA Connect.**

#### **Eligibility requirements:**

The program is open to uninsured and underinsured patients who meet the following eligibility criteria:

- You must be prescribed REBYOTA for an FDA-approved indication
- You reside in the US
- You are being treated by a US-licensed healthcare provider
- Income restrictions apply

**To learn more about the REBYOTA Patient Assistance Program and to see if you qualify, please speak with your doctor.**

<sup>a</sup>Available only for patients who meet eligibility requirements. Programs do not cover the cost of administration, office visits, or any associated costs. Terms and conditions apply. Offer expires 12/31/24.

**Please see Important Safety Information throughout and on page 11. Click to see full [Prescribing Information](#).**





# REBYOTA® RESOURCES

## Ready to talk to your doctor about *C. diff*?

Prepare to ask the right questions. **Create your custom doctor discussion guide** by answering a few questions about your condition.

Scan to build  
your guide or visit  
[REBYOTA.com](https://REBYOTA.com)



## Track your *C. diff* journey

Prepare for your doctor appointments with this printable ***C. diff* diary**. Track medical history, symptoms, questions, food and water intake, and more.

Scan to print  
your diary or visit  
[REBYOTA.com](https://REBYOTA.com)



## Advocate for a loved one

This ***C. diff* Caregiver Checklist** will help you take care of your loved ones with *C. diff* infection.

Scan to download  
your checklist or  
visit [REBYOTA.com](https://REBYOTA.com)



Please see Important Safety Information throughout and on page 11. Click to see full [\*\*Prescribing Information\*\*](#).

# REBYOTA®

## PATIENT STORIES

To watch their full stories or to share your experience with REBYOTA, visit [REBYOTA.com](https://REBYOTA.com).



**“I just knew that if I had *C. diff* again, I wasn’t going to survive. But my *C. diff* didn’t come back after I had REBYOTA.”**

Freda, Clinical Study Patient

Individual results may vary.



**“Had REBYOTA been available sooner, I would have asked for it.”**

Melissa, Clinical Study Patient

Individual results may vary.



**“For me it was one dose and one visit, and that was it. I was able to hug and squeeze my girls again.”**

Patricia, Clinical Study Patient

Individual results may vary.



**“It has been six months since REBYOTA. I have not had another recurrence.”**

Heather, Actual REBYOTA Patient

Individual results may vary.

**Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.<sup>1</sup>**

For more information, please talk to your doctor and see full Prescribing Information enclosed. These patients were compensated for their time. Individual results may vary.

**Please see Important Safety Information throughout and on page 11. Click to see full [Prescribing Information](#).**

  
**REBYOTA®**  
(fecal microbiota, live-jslm) suspension,  
for rectal use



## C. DIFF INFECTION AND ITS RECURRENCE

*C. diff* is a bacteria that can cause an infection in the gut. Symptoms can range from diarrhea to life-threatening damage to the colon.<sup>3</sup> Sometimes a *C. diff* infection can come back more than once. This is called a recurrence.<sup>3,4</sup> If left untreated, it too can cause severe illness, and even death.<sup>3</sup>



**Up to 35%** of people who get a *C. diff* infection may have a recurrence<sup>5,6</sup>



**Up to 65%** of people who experience a recurrence may have a second or third or more<sup>7,8</sup>

**Antibiotics treat *C. diff* infection but can also be the leading cause of *C. diff* recurrence<sup>3,9</sup>**

Please see Important Safety Information throughout and on page 11. Click to see full [\*\*Prescribing Information.\*\*](#)

  
**REBYOTA**<sup>®</sup>  
(fecal microbiota, live-jslm)<sup>suspension, for rectal use</sup>



## C. *DIFF* INFECTION AND ITS RECURRENCE



Only your doctor can diagnose a recurrence of *C. diff* infection. If you have been taking antibiotics and have any of these symptoms, they may indicate a recurrence:

### Symptoms of recurrent *C. diff* infection<sup>10</sup>

- Diarrhea
- Fever
- Stomach tenderness or pain
- Loss of appetite
- Nausea

### If you experience a recurrence...

A recurrence can be mentally demanding and physically challenging. If you experience any symptoms of *C. diff* infection, please start a conversation with your doctor about recurrence prevention.

If left untreated, a *C. diff* infection recurrence can lead to:

- Continued abdominal pain and diarrhea<sup>4</sup>
- Extended stays in the hospital<sup>11</sup>
- Sepsis<sup>12</sup>
- Surgery to remove part of the colon (colectomy)<sup>12</sup>
- Death<sup>5</sup>

### IMPORTANT SAFETY INFORMATION (Continued)

You should report to your doctor any infection you think you may have acquired after administration.

**Please see Important Safety Information throughout and on page 11. Click to see full [Prescribing Information](#).**



# IMPORTANT SAFETY INFORMATION

## INDICATION

REBYOTA (fecal microbiota, live - jslm) is indicated for the prevention of recurrence of *Clostridioides difficile* (*C. diff*) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent *C. diff* infection.

## **Limitation of Use**

REBYOTA is not indicated for the treatment of *C. diff* infection.

## IMPORTANT SAFETY INFORMATION

- You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.
- You should report to your doctor any infection you think you may have acquired after administration.
- REBYOTA may contain food allergens.
- Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).
- REBYOTA has not been studied in patients below 18 years of age.
- Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit [www.FDA.gov/medwatch](http://www.FDA.gov/medwatch) or call 1-800-332-1088.

**Please click to see full [Prescribing Information](#).**



**Please see Important Safety Information throughout and on page 11. Click to see full [Prescribing Information](#).**





## REFERENCES

1. REBYOTA. Prescribing Information. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2022.
2. Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double blind, placebo controlled trial with a Bayesian primary analysis for the prevention of recurrent *Clostridioides difficile* infection. *Drugs*. 2022;82(15):1527-1538.
3. Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and *Clostridium difficile* infection: is there a relationship with inflammatory bowel disease? *Therap Adv Gastroenterol*. 2013;6(1):53-68.
4. Antharam VC, Li EC, Ishmael A, et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in *Clostridium difficile* infection and nosocomial diarrhea. *J Clin Microbiol*. 2013;51(9):2884-2892.
5. Lessa FC, Mu Y, Bamberg WM, et al. Burden of *Clostridium difficile* infection in the United States. *N Engl J Med*. 2015;372(9):825-834.
6. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of *Clostridium difficile* infection: fidaxomicin versus vancomycin. *Clin Infect Dis*. 2012;55(suppl 2):S154-S161.
7. Kelly CP. Can we identify patients at high risk of recurrent *Clostridium difficile* infection? *Clin Microbiol Infect*. 2012;18(suppl 6):21-27.
8. Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. *Clostridium difficile* infection. *Nat Rev Dis Primers*. 2016;2:16020.
9. McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis*. 2018;66(7):e1-e48.
10. Centers for Disease Control and Prevention website. What is C. diff? <https://www.cdc.gov/cdiff/what-is.html>. Accessed March 15, 2024.
11. Nelson WW, Scott TA, Boules M, et al. Health care resource utilization and costs of recurrent *Clostridioides difficile* infection in the elderly: a real-world claims analysis. *J Manag Care Spec Pharm*. 2021;27(7):828-838.
12. Feuerstadt P, Boules M, Stong L, et al. Clinical complications in patients with primary and recurrent *Clostridioides difficile* infection: a real-world data analysis. *SAGE Open Med*. 2021;9:2050312120986733.

**Please see Important Safety Information throughout and on page 11. Click to see full [Prescribing Information](#).**





**The content in this brochure is for informational purposes only and is not intended to replace a discussion with a healthcare professional.**

Scan to visit  
[REBYOTA.com](https://REBYOTA.com)



Microbiome  
Therapeutics  
Development